News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Concert Pharmaceuticals, Inc. and Fast Forward, LLC Announce Collaboration to Advance Novel Treatment for Spasticity and Pain in Multiple Sclerosis


3/5/2012 6:31:06 AM

LEXINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society’s subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS). Fast Forward will commit funding to support the program for prospective clinical stage development.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES